Browse

When the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied.

The decision to move ahead with new products in the absence of FDA authorization could spur other big manufacturers to do the same, one tobacco-nicotine expert said.

Bristol Myers Squibb announced in early June that it is pausing its CAR‑T therapy trials targeting autoimmune diseases after the trials reported life‑threatening side effects. The company informed…